- HIV TEST
- STIs TEST
Hospital Universitario Valle de Hebrón : What makes us unique at Vall d’Hebron Barcelona Hospital Campus is our reputation. On the one hand, we are a reference centre in 25 CSUR accreditations (Centres, Departments and Units of Reference in the National Health System), guaranteeing access to quality, and safe and efficient healthcare for people with conditions that require highly specialised care. On the other hand, at a European level, we are part of ten European reference networks in rare diseases.
The goal of the Infectious Diseases Department is the prevention, control and treatment of these diseases, through three main areas: care, teaching (both undergraduate and postgraduate), and research (between the Vall d’Hebron Hospital and the Autonomous University of Barcelona).
At the Infectious Diseases Department, our care is structured into the following areas: hospitalisation, outpatient care, nosocomial infection control (infections contracted during a hospital stay), prevention and treatment of infection in HIV- immunodepressed patients (with solid or haematological neoplasia, bone marrow transplant or solid organ); international health and imported infections, and the HIV+ patients ward.
The Infectious Diseases Research Group (coordinated by Dr Benito Almirante) of the Vall d’Hebron Research Institute carries out clinical research that is closely linked to the care we provide, and which groups together the various Research Areas. We should also highlight our animal experimentation laboratory, within the Vall d’Hebron University Research Institute, which allows us to experiment and obtain results using various animal models, with the ultimate goal of trying to improve the prognosis of various serious infectious pathologies in humans. The current lines of research are:
– Nosocomial infection
– Serious community infection
– HIV/AIDS infection
– Infection in transplants
– Infection in oncohaematology
– Experimental models of infections
These lines of research are externally funded through research projects funded by the pharmaceutical industry or by public entities, as well as receiving funding as a member of thematic cooperative research networks organised by the Carlos III Health Institute (REIPI and RIS).